By Josh White
Date: Wednesday 27 Aug 2025
(Sharecast News) - Faron Pharmaceuticals reported a series of first-half clinical and financial milestones on Wednesday, as it advanced its lead asset, bexmarilimab, through late-stage development in high-risk myelodysplastic syndromes (HR-MDS).
By Josh White
Date: Monday 18 Aug 2025
(Sharecast News) - Faron Pharmaceuticals said on Monday that it has secured a clear regulatory pathway for the potential approval of its lead cancer therapy bexmarilimab, following positive feedback from the US Food and Drug Administration.
By Josh White
Date: Wednesday 21 May 2025
(Sharecast News) - Faron Pharmaceuticals announced the appointment of Ralph Hughes as its chief business officer on Wednesday, effective 28 May, as the clinical-stage biopharma firm sharpened its focus on commercial strategy, business development and market access.
Currency | UK Pounds |
Share Price | 198.00p |
Closing Price Change | 2.00p |
% Change | 0.00 % |
52 Week High | 0.000p |
52 Week Low | 0.000p |
Volume | 0 |
Shares Issued | 116.95m |
Value |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Price Trend |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Income | ![]() |
---|
Growth | ![]() |
---|
Strong Buy | 1 |
Buy | 4 |
Neutral | 0 |
Sell | 0 |
Strong Sell | 1 |
Total | 6 |
No dividends found |
Time | Volume / Share Price |
0 @ 0.000p |
CFO | Yrjö E K Wichmann |
CEO | Juho Jalkanen |
Chair | Tuomo Pätsi |
You are here: research